Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Trial of CRLX101 in Advanced Gastric and Esophageal Cancer
NCT01612546Phase 2Completed
- Sponsor
- City of Hope
- Start
- Nov 2012
- Primary completion
- Jan 2015
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of CRLX101 in gastric cancer (GC), esophageal cancer, gastroesophageal junction adenocarcinoma, sponsored by City of Hope. Started Nov 2012; status: completed.
02
Drugs
CRLX101
03
Conditions
gastric cancer (GC)esophageal cancergastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01612546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01612546.